"rationale","instanceType","uuid:ID","versionIdentifier","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","39e9d7c9-42ac-45ab-9d62-ad5206e42e9e","2","StudyVersion_1"
